Reported revenues of $227.2m, down 17% on 1HFY19
• Reported EBITDA of $34.6m, a decrease of 47% on 1HFY19
• Underlying EBITDA of $47.4m, a decrease of 42% on 1HFY19
• Reported net loss after tax of $17.5m driven by lower earnings and restructuring expenses
• Net operating cashflow of $46.2m down 14% on 1HFY19
• Licensed novel oral contraceptive E4/DRSP in the US
• Generic NUVARING® complete response letter submitted to the US Food and Drug
Administration (FDA) with launch anticipated in CY20
• Filed three generic products with the FDA including a potential first-to-market women’s health
product
• Significant spend base reduction of $20m (annualised)
- Forums
- ASX - By Stock
- MYX
- Ann: 2020 Half Year Media Release
Ann: 2020 Half Year Media Release, page-2
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.38 |
Change
0.440(11.2%) |
Mkt cap ! $372.6M |
Open | High | Low | Value | Volume |
$4.40 | $4.79 | $4.18 | $2.649M | 590.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1271 | $4.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.44 | 1271 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 4.200 |
1 | 3000 | 4.110 |
1 | 1000 | 4.080 |
1 | 180 | 4.060 |
8 | 9994 | 4.050 |
Price($) | Vol. | No. |
---|---|---|
4.450 | 6200 | 1 |
4.500 | 450 | 1 |
4.700 | 367 | 2 |
4.730 | 1805 | 1 |
4.740 | 4111 | 2 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
MYX (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online